Marsh
MRSH
$167.71
-1.83%
Marsh McLennan is a global professional services firm operating in the Financial Services sector, specifically within the Insurance Brokers and Consulting industries. The company provides advice and solutions in risk, strategy, and human capital through its two main segments: Risk and Insurance Services, which includes its flagship Marsh brokerage and Guy Carpenter reinsurance specialist, and Consulting, which comprises Mercer and Oliver Wyman. As a dominant market leader and one of the world's largest insurance brokers and consulting firms, it is distinguished by its global scale, diversified service portfolio, and deep client relationships. The current investor narrative is focused on the company's resilience and growth trajectory in a hardening insurance market, though recent stock performance has lagged the broader market, raising questions about its valuation and the sustainability of its margin expansion amid potential economic headwinds.…
MRSH
Marsh
$167.71
Investment Opinion: Should I buy MRSH Today?
Rating & Thesis: Based on a synthesis of the data, Marsh McLennan is a Hold. The core thesis is that the stock's high-quality fundamentals are currently overshadowed by powerful negative momentum and sentiment, suggesting investors should wait for a stabilization in price action or a clearer inflection in business trends before committing new capital. Analyst sentiment is mixed, reflecting this uncertainty.
Supporting Evidence: The Hold rating is supported by four key data points. First, valuation is reasonable but not compelling, with a forward P/E of 15.03x sitting near the midpoint of its own historical range. Second, while revenue grew 8.7% YoY in Q4, sequential quarterly declines suggest growth is moderating. Third, profitability remains strong with a 27.55% ROE and $5.0B in TTM FCF, providing a solid floor. Fourth, the stock offers a modest 1.88% dividend yield, adding a total return component while investors wait for a catalyst.
Risks & Conditions: The two biggest risks to the thesis are 1) a continuation of the earnings and margin volatility seen in recent quarters, and 2) a break below the key $164.89 technical support level, which could trigger further selling. This Hold rating would upgrade to a Buy if the forward P/E compresses further to the low-14x range (implying a price near $173 based on $12.33 EPS) on sustained negative sentiment, or if quarterly revenue growth re-accelerates above 10% with stable margins. It would downgrade to a Sell if the stock breaks below $164.89 on high volume with no fundamental recovery in sight. Relative to its own history and given its quality, the stock appears fairly valued to slightly undervalued, but not deeply enough to overcome the negative technical picture.
Sign up to view all
MRSH 12-Month Price Forecast
The AI assessment is neutral with medium confidence. Marsh is a high-quality company caught in a negative momentum vortex. Its superb profitability and cash flow generation argue against a deep, permanent decline, but the persistent downtrend and earnings volatility prevent a bullish call. The stock likely treads water (base case, 60% probability) as it works through cyclical headwinds. The stance would upgrade to bullish on a confirmed technical reversal above $190 coupled with evidence of margin stability. It would downgrade to bearish on a decisive break below the $164.89 support on deteriorating fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Marsh's 12-month outlook, with a consensus price target around $218.02 and implied upside of +30.0% versus the current price.
Average Target
$218.02
8 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
8
covering this stock
Price Range
$134 - $218
Analyst target range
Analyst coverage for Marsh is substantial, with 8 analysts providing estimates, indicating strong institutional interest. The consensus sentiment appears mixed, as evidenced by recent rating actions including a downgrade from Mizuho to 'Neutral' and an upgrade from Raymond James to 'Strong Buy' in February 2026, alongside reiterations of 'Overweight' and 'Market Perform' ratings from other firms. The average EPS estimate for the period is $12.33, with a range from $11.63 to $12.94, and the average revenue estimate is $31.34 billion; however, specific price targets and a consensus recommendation are not provided in the data, preventing a calculation of implied upside or downside from the current price. The wide EPS estimate range of $1.31 signals some uncertainty among analysts regarding the company's near-term earnings power, which could be driven by debates over the sustainability of insurance market conditions, consulting demand, or interest expense impacts.
Bulls vs Bears: MRSH Investment Factors
The investment debate for Marsh McLennan centers on a clash between its strong fundamental quality and its deeply negative price momentum. The bull case is anchored in the company's exceptional profitability (27.55% ROE), robust free cash flow ($5.0B), and defensive business model, all trading at a reasonable forward P/E of 15x. The bear case is driven by severe technical underperformance (-37.78% relative strength), a clear downtrend, and signs of earnings volatility. Currently, the bearish price action presents stronger immediate evidence, overwhelming the solid fundamentals. The single most important tension is whether the market's negative sentiment, likely driven by fears of an economic slowdown impacting consulting demand and insurance brokerage cycles, will persist long enough to further compress the valuation of an otherwise high-quality franchise.
Bullish
- Strong Free Cash Flow Generation: The company generated $5.0 billion in TTM free cash flow, providing significant financial flexibility. This robust cash flow supports the dividend (1.88% yield), share buybacks, and strategic acquisitions without straining the balance sheet.
- High Return on Equity: Marsh's ROE of 27.55% is exceptionally high, indicating efficient use of shareholder capital. This level of profitability is a key competitive advantage and a hallmark of a high-quality business model.
- Resilient Revenue Growth: Q4 2025 revenue grew 8.7% year-over-year to $6.595 billion, demonstrating resilience despite economic uncertainty. This steady growth is underpinned by the company's market-leading position in insurance brokerage and consulting.
- Attractive Forward Valuation: The stock trades at a forward P/E of 15.03x, a significant discount to its trailing P/E of 21.72x. This forward multiple suggests the market is pricing in reasonable growth expectations, potentially offering a margin of safety.
Bearish
- Severe Underperformance vs. Market: The stock has significantly underperformed, with a 1-year price change of -7.19% compared to the SPY's +30.59% gain. This -37.78% relative strength figure indicates deep-seated negative investor sentiment or sector-specific concerns.
- Persistent Technical Downtrend: The stock is in a clear downtrend, trading at $170.1, down 28% from its 52-week high of $235.78. Negative momentum is confirmed by 1-month and 3-month price changes of -2.35% and -7.13%, respectively.
- Earnings Volatility and Margin Pressure: Sequential quarterly revenue declined from $7.061B in Q1 2025 to $6.595B in Q4 2025, and the Q4 net margin of 12.45% was below the Q1 level. This indicates potential cyclicality and margin pressure in the consulting segment.
- Moderate Financial Leverage: A debt-to-equity ratio of 1.42 indicates moderate leverage. In a rising interest rate environment, this could pressure earnings through higher interest expenses, as seen with $235M in Q4 2025 interest expense.
MRSH Technical Analysis
Marsh's stock is in a pronounced downtrend, with a 1-year price change of -7.19% as of April 24, 2026, significantly underperforming the SPY's +30.59% gain. The stock is trading near the lower end of its 52-week range, with a current price of $170.1 compared to a 52-week high of $235.78 and a low of $164.89; this positions it at approximately 24% above its 52-week low, suggesting it may be approaching a potential value zone but remains in a bearish phase. The 1-month and 3-month price changes of -2.35% and -7.13%, respectively, confirm persistent negative momentum that aligns with the longer-term downtrend, indicating no near-term reversal signal. The stock's beta of 0.749 suggests it is approximately 25% less volatile than the broader market, which has provided some downside cushion but has not prevented significant relative weakness, as evidenced by a -37.78% 1-year relative strength figure. Key technical levels are clearly defined, with immediate support at the 52-week low of $164.89 and resistance near the 52-week high of $235.78; a decisive break below support could trigger further selling, while a recovery above the recent trading range near $190 is needed to signal a potential trend change. The stock's low beta implies it is a lower-risk holding during market downturns, but its persistent underperformance suggests company-specific or sector-related concerns are outweighing this defensive characteristic.
Beta
0.75
0.75x market volatility
Max Drawdown
-11.6%
Largest decline past year
52-Week Range
$165-$236
Price range past year
Annual Return
-8.5%
Cumulative gain past year
| Period | MRSH Return | S&P 500 |
|---|---|---|
| 1m | -3.3% | +10.5% |
| 3m | -10.9% | +3.9% |
| 6m | -8.5% | +5.4% |
| 1y | -8.5% | +29.6% |
| ytd | -8.5% | +5.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRSH Fundamental Analysis
Marsh's revenue trajectory shows steady growth, with Q4 2025 revenue of $6.595 billion representing an 8.7% year-over-year increase; however, examining sequential quarters reveals some volatility, with revenue declining from $7.061 billion in Q1 2025 to the Q4 level, indicating potential seasonal patterns or a moderation from a strong start to the year. The company is solidly profitable, reporting Q4 2025 net income of $821 million and a net margin of 12.45%, with a gross margin of 40.29% and an operating margin of 18.48%; these margins have shown stability, with the Q4 operating margin slightly above the 18.42% from Q3 2025, demonstrating disciplined cost management. The balance sheet and cash flow position is robust, with a debt-to-equity ratio of 1.42 indicating moderate leverage, a strong return on equity of 27.55%, and substantial free cash flow generation of $5.001 billion on a trailing twelve-month basis, providing ample internal resources for dividends, share buybacks, and strategic acquisitions without reliance on excessive external financing.
Quarterly Revenue
$6.6B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.40%
Latest Quarter
Free Cash Flow
$5.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRSH Overvalued?
Given Marsh's consistent profitability with a positive net income of $821 million in its latest quarter, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 21.72x and a forward PE of 15.03x, with the forward multiple's discount to the trailing figure implying the market expects earnings growth or a normalization from potentially elevated recent earnings. Compared to sector averages, which are not provided in the data, a direct peer comparison cannot be quantified; however, a forward PE of 15x for a high-quality, market-leading financial services firm with a 27.55% ROE could be viewed as reasonable if it is in line with or at a discount to its peer group. Historically, the stock's own trailing PE has fluctuated significantly, ranging from a low near 15.77x in early 2021 to a high above 44x in late 2022; the current 21.72x multiple sits near the midpoint of this historical range, suggesting the stock is neither excessively cheap nor expensive based on its own history, but rather priced for moderate growth expectations.
PE
21.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 16x~44x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Marsh faces risks from moderate financial leverage, with a debt-to-equity ratio of 1.42. In a higher-for-longer interest rate environment, the company's substantial interest expense ($235M in Q4 2025) could pressure net income. Furthermore, revenue and margin volatility is evident, with Q4 2025 operating income of $1.22B down significantly from $2.01B in Q1 2025, indicating sensitivity to economic cycles, particularly in the consulting segment. The company's valuation also depends on sustaining high profitability; a decline from its current 27.55% ROE could trigger a significant multiple contraction.
Market & Competitive Risks: The primary market risk is valuation compression. The stock trades at a forward P/E of 15.03x, which, while reasonable, could de-rate further if growth decelerates or if the market continues to rotate away from financial services. Its low beta of 0.749 has not protected it from severe relative underperformance (-37.78% vs. SPY), suggesting company or sector-specific headwinds are dominant. Competitive risks include potential disintermediation in insurance brokerage and pressure on consulting fees during an economic downturn, which could challenge the 8.7% YoY revenue growth rate.
Worst-Case Scenario: The worst-case scenario involves a sharp economic downturn leading to a dual collapse in consulting demand and a softening insurance market, compressing commissions and fees. This would trigger earnings misses relative to the $12.33 average EPS estimate, leading to analyst downgrades and a full valuation de-rating. In this adverse scenario, the stock could realistically re-test its 52-week low of $164.89, representing a -3.1% decline from the current $170.1. A more severe bear case, factoring in historical max drawdowns, could see a drop towards the $150-$160 range, implying a potential loss of -6% to -12% from current levels.
FAQ
The key risks of holding MRSH are, in order of severity: 1) Market/Sentiment Risk: Severe underperformance (-7.19% 1-year return vs. SPY +30.59%) could persist, driven by sector rotation away from financials. 2) Operational Risk: Earnings and margin volatility, as seen in the drop from Q1 to Q4 2025 operating income, indicates sensitivity to economic cycles, particularly in consulting. 3) Financial Risk: Moderate leverage (Debt/Equity of 1.42) coupled with high interest expense ($235M in Q4) could pressure profits if rates remain elevated. 4) Valuation Risk: A further de-rating of the P/E multiple is possible if growth decelerates below current expectations.
The 12-month forecast for MRSH is framed by three scenarios with associated probabilities. The Base Case (60% probability) sees the stock trading between $180 and $200, assuming it meets the $12.33 EPS consensus and the P/E multiple stabilizes. The Bull Case (25% probability) targets $210 to $235 on an earnings beat and multiple expansion. The Bear Case (15% probability) risks a decline to $165-$175 if earnings miss and support breaks. The most likely outcome is the Base Case, predicated on the assumption that the company's high-quality fundamentals eventually halt the downtrend, leading to range-bound consolidation.
Based on the provided data, MRSH appears fairly valued to slightly undervalued. Its forward P/E of 15.03x represents a meaningful discount to its trailing P/E of 21.72x, implying the market expects earnings growth normalization. While a direct peer comparison is unavailable, a 15x multiple for a company with a 27.55% ROE and stable cash flows is not demanding. Historically, the stock's own P/E has ranged from ~16x to 44x, placing the current multiple near the midpoint. The valuation implies the market is paying a fair price for moderate, single-digit earnings growth, not a premium for hyper-growth.
MRSH is a good stock to buy for patient, long-term investors seeking a high-quality, defensive business at a fair price, but not for traders seeking near-term momentum. The stock offers a reasonable forward P/E of 15x, a 1.88% dividend, and exceptional profitability (27.55% ROE). However, it is in a clear downtrend with -37.78% relative strength vs. the market, indicating significant negative sentiment. It is a good buy for those who can tolerate near-term volatility and are looking to build a position in a world-class franchise, ideally on further weakness towards the $165 support level.
MRSH is unequivocally suitable for a long-term investment horizon, with a suggested minimum holding period of 3-5 years. Its low beta (0.749) and dividend provide characteristics for a core holding, not a short-term trade. The current negative momentum and lack of near-term catalysts make it poorly suited for short-term traders seeking quick gains. Long-term investors can benefit from the company's durable competitive advantages, global scale, and capital return program while waiting for the business cycle and market sentiment to turn more favorable.